查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1317837

肺癌藥物市場：按分子（生物製劑、小分子）、疾病（NSCLC、SCLC）、癌症類型、治療方法、分佈 - 全球預測 2023-2030

Lung Cancer Therapeutics Market by Molecules (Biologics, Small Molecules), Disease (NSCLC, SCLC), Cancer Type, Therapy, Distribution - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球肺癌藥物市場將大幅成長250.4億美元，年複合成長率為8.37%，預計到2030年將達到440.3億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球肺癌治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球肺癌藥物市場規模及預測如何？

2.在預測期內，COVID-19對全球肺癌治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球肺癌藥物市場需要投資哪些產品/細分市場/應用/領域？

4.貴公司在全球肺癌藥物市場的競爭策略為何？

5.全球肺癌藥物市場的技術趨勢和法律規範是什麼？

6.全球肺癌藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入肺癌藥物全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 全球肺癌盛行率增加
      • 加強醫療保健意識不斷增強
      • 政府對肺癌治療的承諾不斷增加
    • 抑制因素
      • 學名藥的廣泛供應
      • 接受肺癌治療的患者預期壽命縮短
    • 機會
      • 擴大新治療方法研究和領域的資金
      • 引進免疫療法等先進療法
    • 任務
      • 放療和化療副作用的風險
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 依分子分類的肺癌治療藥物市場

  • 生物製品
  • 低分子

第7章 肺癌藥物市場：依疾病分類

  • NSCLC
  • SCLC

第8章 按癌症類型分類的肺癌治療藥物市場

  • 肺類癌
  • 非小細胞肺癌
  • 小細胞肺癌

第9章 依療法分類的肺癌治療藥物市場

  • 化學處理
  • 免疫療法
    • 阿替利珠單抗
    • 度瓦魯單抗
    • 納武單抗
    • 帕博利珠單抗
  • 放射治療
    • 外樑
    • 內樑
    • 系統性的
  • 標靶治療
    • Bevacizumab
    • 達拉非尼/曲美替尼
    • Erlotinib Hydrochloride
    • 奧西替尼

第10章 肺癌治療藥物市場分佈

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章美洲肺癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太肺癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲肺癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第15章上市公司名單

第16章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-437A5D08AE40

The Global Lung Cancer Therapeutics Market is forecasted to grow significantly, with a projected USD 25.04 billion in 2023 at a CAGR of 8.37% and expected to reach a staggering USD 44.03 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Lung Cancer Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Lung Cancer Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Molecules, market is studied across Biologics and Small Molecules. The Small Molecules is projected to witness significant market share during forecast period.

Based on Disease, market is studied across NSCLC and SCLC. The SCLC is projected to witness significant market share during forecast period.

Based on Cancer Type, market is studied across Lung Carcinoid Tumor, Non-small Cell Lung Cancer, and Small Cell Lung Cancer. The Small Cell Lung Cancer is projected to witness significant market share during forecast period.

Based on Therapy, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy. The Immunotherapy is further studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab. The Radiation Therapy is further studied across External Beam, Internal Beam, and Systemic. The Targeted Therapy is further studied across Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, and Osimertinib. The Chemotherapy is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacies, Online Phramacies, and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Lung Cancer Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Lung Cancer Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Lung Cancer Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Lung Cancer Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Lung Cancer Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Lung Cancer Therapeutics Market?

6. What is the market share of the leading vendors in the Global Lung Cancer Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Lung Cancer Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Lung Cancer Therapeutics Market, by Molecules, 2022 vs 2030
  • 4.3. Lung Cancer Therapeutics Market, by Disease, 2022 vs 2030
  • 4.4. Lung Cancer Therapeutics Market, by Cancer Type, 2022 vs 2030
  • 4.5. Lung Cancer Therapeutics Market, by Therapy, 2022 vs 2030
  • 4.6. Lung Cancer Therapeutics Market, by Distribution, 2022 vs 2030
  • 4.7. Lung Cancer Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of lung cancer across the globe
      • 5.1.1.2. Growing awareness regarding enhanced health care
      • 5.1.1.3. Rising government initiatives for lung cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Huge availability of the generic drugs
      • 5.1.2.2. Reduced life expectancy of patients undertaking lung cancer treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding in the field of research and development of new treatment
      • 5.1.3.2. Adoption of advanced therapy such as immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of side effects of radiation and chemotherapy
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Lung Cancer Therapeutics Market, by Molecules

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Small Molecules

7. Lung Cancer Therapeutics Market, by Disease

  • 7.1. Introduction
  • 7.2. NSCLC
  • 7.3. SCLC

8. Lung Cancer Therapeutics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Lung Carcinoid Tumor
  • 8.3. Non-small Cell Lung Cancer
  • 8.4. Small Cell Lung Cancer

9. Lung Cancer Therapeutics Market, by Therapy

  • 9.1. Introduction
  • 9.2. Chemotherapy
  • 9.3. Immunotherapy
    • 9.3.1. Atezolizumab
    • 9.3.2. Durvalumab
    • 9.3.3. Nivolumab
    • 9.3.4. Pembrolizumab
  • 9.4. Radiation Therapy
    • 9.4.1. External Beam
    • 9.4.2. Internal Beam
    • 9.4.3. Systemic
  • 9.5. Targeted Therapy
    • 9.5.1. Bevacizumab
    • 9.5.2. Dabrafenib/Trametinib
    • 9.5.3. Erlotinib Hydrochloride
    • 9.5.4. Osimertinib

10. Lung Cancer Therapeutics Market, by Distribution

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Phramacies
  • 10.4. Retail Pharmacies

11. Americas Lung Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Lung Cancer Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Lung Cancer Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER THERAPEUTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2022 VS 2030 (%)
  • FIGURE 5. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
  • FIGURE 6. LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
  • FIGURE 7. LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
  • FIGURE 8. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
  • FIGURE 9. LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 10. LUNG CANCER THERAPEUTICS MARKET DYNAMICS
  • FIGURE 11. LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 20. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 21. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 5. LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 8. LUNG CANCER THERAPEUTICS MARKET SIZE, BY NSCLC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. LUNG CANCER THERAPEUTICS MARKET SIZE, BY SCLC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. LUNG CANCER THERAPEUTICS MARKET SIZE, BY LUNG CARCINOID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 15. LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 17. LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. LUNG CANCER THERAPEUTICS MARKET SIZE, BY INTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. LUNG CANCER THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. LUNG CANCER THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DABRAFENIB/TRAMETINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. LUNG CANCER THERAPEUTICS MARKET SIZE, BY ERLOTINIB HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. LUNG CANCER THERAPEUTICS MARKET SIZE, BY OSIMERTINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHRAMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 249. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 265. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 273. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 281. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 289. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 297. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 305. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 313. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 321. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 322. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 323. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 329. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 330. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 331. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030